Background REGEN-COV (previously known as REGN-COV2), a combination of the monoclonal
antibodies casirivimab and imdevimab, has been shown to markedly reduce the risk of …

Human metapneumovirus (HMPV) is a member of the subfamily Pneumovirinae within the
family Paramyxoviridae. Other members of this subfamily, respiratory syncytial virus and avian …

Importance Easy-to-administer anti–SARS-CoV-2 treatments may be used to prevent
progression from asymptomatic infection to symptomatic disease and to reduce viral carriage. …

Aim Adjuvanted influenza vaccines can overcome the poor antibody response of conventional
non-adjuvanted vaccines in the elderly. We evaluated the immunogenicity, safety and …

Background Respiratory syncytial virus (RSV) is a major cause of childhood medically
attended respiratory infection (MARI). Methods We conducted a randomized, double-blind, …

While new vaccines for SARS-CoV-2 are authorized based on neutralizing antibody (nAb)
titer against emerging variants of concern, an analogous pathway does not exist for …

Fibrodysplasia ossificans progressiva (FOP) is a rare disease characterized by heterotopic
ossification (HO) in connective tissues and painful flare-ups. In the phase 2 LUMINA-1 trial, …

Background There is an unmet need for COVID-19 prevention in patient populations who
have not mounted or are not expected to mount an adequate immune response to complete …

Background The open-label RECOVERY study reported improved survival in hospitalized,
SARS-CoV-2 seronegative patients treated with casirivimab and imdevimab (CAS + IMD). …

Objectives A phase 1, double-blind, placebo-controlled trial was conducted to evaluate the
safety, tolerability, and exploratory efficacy of repeat monthly doses of subcutaneous (SC) …